Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very
expensive. There is a need to explore effective natural therapies against HCV that are less
toxic and more cost-effective.
37 chronic HCV infected patients were randomized into two groups and treated with PEG
interferon plus ribavirin for the first group or Biobran, an arabinoxylan from rice bran (1
g/day) for the second group. Viremia level, liver enzymes, γ-interferon (IFN-γ) levels in
serum, and toxicity were checked before and three months after treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Cairo University
Collaborators:
Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan University of California, Los Angeles